Multiple endogenous growth factor receptors (PRP-GFRs)

Multiple endogenous growth factor receptors represent a collective therapeutic target activated by the administration of Platelet-Rich Plasma (PRP). PRP contains a concentrated milieu of native ligands, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Vascular Endothelial Growth Factor (VEGF), and Epidermal Growth Factor (EGF), which bind to their respective high-affinity receptors on target cells (PMID: 22454634). This multi-target activation triggers complex intracellular signaling cascades, such as the MAPK and PI3K/Akt pathways, which orchestrate tissue repair, angiogenesis, and extracellular matrix synthesis (StatPearls: Platelet Rich Plasma). While widely utilized in orthopedics, sports medicine, and dermatology for conditions like osteoarthritis and chronic wounds, the therapeutic effect is mediated by the synergistic action of these various receptors rather than a single molecular pathway (PMID: 30234333). The clinical efficacy of targeting these receptors via PRP is often influenced by the individual's baseline platelet quality and the specific preparation method used, leading to challenges in therapeutic standardization.

Other names

Platelet-rich plasma growth factor receptorsPRP-associated receptorsEndogenous growth factor receptor complexAutologous growth factor receptors

Simultaneous activation of multiple transmembrane receptors (e.g., PDGFR, VEGFR, TGFBR) by a concentrated cocktail of autologous ligands, triggering downstream MAPK/ERK, PI3K/Akt, and Smad signaling pathways to promote cellular repair.